Health
Neutrolis announces development of first-in-class therapy to target NETs in COVID-19 patients – News-Medical.Net
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemica…
Neutrolis, a biotechnology company developing therapeutics that target neutrophils, the most abundant immune cells in the body, today announced the development of NTR-441, a first-in-class DNASE1L3 enzyme analog that has the potential to rapidly and systemically clear neutrophil extracellular traps (NETs) for severe cases of COVID-19. NETs are a fundamental arm of the immune system and play an important role in chronic and acute diseases.
We believe NETs are the common factor that explains the …
-
Noosa News22 hours agoIKEA Has Just Revealed Its Collab with Trendsetting Designer Gustaf Westman, Bringing Sculptural Shapes to the Holiday Season
-
Noosa News22 hours agoMan injured, cars destroyed at Tyres and More shop
-
General21 hours agoThree men to be sentenced over Mid North Coast Correctional Centre bashing
-
Business15 hours agoBrokers name 3 quality ASX 200 shares to buy today